Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report published on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MRNS has been the topic of several other research reports. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research note on Monday, September 23rd. Royal Bank of Canada cut their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. Jefferies Financial Group restated a “hold” rating and set a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Finally, JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.07.

Marinus Pharmaceuticals Trading Down 2.6 %

Marinus Pharmaceuticals stock opened at $0.32 on Friday. The firm has a market capitalization of $17.85 million, a P/E ratio of -0.12 and a beta of 1.26. The stock has a fifty day moving average price of $1.39 and a 200 day moving average price of $1.37. Marinus Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The firm had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same period last year, the firm posted ($0.61) EPS. As a group, equities analysts predict that Marinus Pharmaceuticals will post -1.92 EPS for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP grew its position in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 817,050 shares during the last quarter. abrdn plc grew its position in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Marinus Pharmaceuticals by 70.3% during the third quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after buying an additional 183,396 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals during the second quarter worth about $28,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Marinus Pharmaceuticals during the second quarter worth about $64,000. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.